Cart
sales@molnova.com
Tivozanib hydrochloride hydrate
CAS No. 682745-41-1
Tivozanib hydrochloride hydrate( —— )
Catalog No. M35722 CAS No. 682745-41-1
Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) is an orally active, selective, and potent vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, and VEGFR-3.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 50 | In Stock |
|
| 10MG | 70 | In Stock |
|
| 25MG | 112 | In Stock |
|
| 50MG | 161 | In Stock |
|
| 100MG | 238 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 593 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTivozanib hydrochloride hydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) is an orally active, selective, and potent vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, and VEGFR-3.
-
DescriptionTivozanib hydrochloride hydrate is a selective and orally activeVEGFR tyrosine kinase inhibitor with IC50 of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC).
-
In VitroTivozanib hydrochloride hydrate inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3.
-
In VivoTivozanib hydrochloride hydrate (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number682745-41-1
-
Formula Weight509.34
-
Molecular FormulaC22H22Cl2N4O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (490.83 mM; Ultrasonic )
-
SMILESO.Cl.COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Motzer RJ, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013 Oct 20;31(30):3791-9.?
molnova catalog
related products
-
GW297361
GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 and Pho85 were 20 nM and 400 nM, respectively.
-
Regorafenib
A potent multikinase inhibitor that potently inhibits these endothelial cell kinases in biochemical and cellular kinase phosphorylation assays with nanomolar range (IC50=3-200 nM).
-
Bevacizumab
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
